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Abstract
Objective—Bronchopulmonary dysplasia (BPD) is the most common cause of pulmonary
morbidity in premature infants and is associated with life-long morbidities. Developing drugs for
the prevention of BPD would improve public health. We sought to determine characteristics of
favorable randomized controlled trials (RCTs) of drugs for BPD prevention.
Evidence review—We searched MEDLINE and EMBASE from 1992–2014 using the MeSH
terms “BPD” and “respiratory distress syndrome, newborn.” We included a Cochrane Library
search to ensure inclusion of all available RCTs. We identified RCTs with BPD as a primary or
secondary outcome and determined the definition of BPD used by the study. We determined
whether a phase I or phase II study—to determine drug safety, efficacy, or optimal dose—was
performed prior to the RCT. Finally, we searched the Cochrane Library for meta-analyses for each
drug and used the results of available meta-analyses to define a favorable versus unfavorable RCT.
Findings—We identified 2026 articles; 47 RCTs met our inclusion criteria encompassing 21
drugs; 5 of the drugs reduced the incidence of BPD. We found data from phase I or II studies for
16 of the drugs, but only 1 demonstrated a reduction of BPD.
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Conclusions and relevance—The majority of the drugs studied in RCTs failed to reduce the
incidence of BPD. Performing early-phase studies prior to phase III trials might provide necessary
information on drugs and drug doses capable of preventing BPD, thus informing the development
of future RCTs.
Keywords
bronchopulmonary dysplasia; randomized controlled trials; infant; newborn; FDA; labeling
Introduction
Bronchopulmonary dysplasia (BPD) is the most common cause of pulmonary morbidity in
premature infants.1 Infants with BPD are at increased risk for death, and survivors have life-
long morbidities.1–5 Despite the increased survival of extremely premature infants, BPD
remains a major morbidity.1–4,6 Approximately 40% of infants born between 22 and 28
weeks gestation are diagnosed with BPD, defined as oxygen supplementation at 36 weeks
postmenstrual age (PMA).1,5,7 Developing drugs to prevent or treat BPD, a major goal of
neonatal care over the past 20 years, would substantially decrease long-term morbidity and
reduce healthcare costs of premature infants.
High-quality randomized controlled trials (RCTs) are the gold standard for determining the
efficacy of drugs. Over the past 20 years, multiple RCTs have examined the efficacy of
drugs for prevention or treatment of BPD, but few drugs have shown favorable results.8
Potential reasons for unfavorable RCTs include 1 or more of the following: contamination of
the control group, incorrect biological basis for the intervention, variability in patient
characteristics and management between centers, inadequate power to detect small effects,
paucity of preliminary data, or a confounded primary outcome due to inconsistent
definitions of BPD.9
The purpose of this systematic review was to examine RCTs of drugs for BPD prevention
and determine: 1) if they were preceded by phase I and phase II (early-phase) trials, and 2)
the definition of BPD used.
Methods
We followed the “Preferred reporting items for systematic reviews and meta-analyses”
(PRISMA) statement for reporting of this systematic review.10
Search strategy
We conducted a search of the Cochrane database to identify drugs studied for BPD
prevention. We used this list as MeSH terms or equivalent to compose searches of
MEDLINE and EMBASE for RCTs evaluating these drugs from 1992–2014 (vitamin A,
superoxide dismutase, N-acetylcysteine, nitric oxide, erythromycin, histamine antagonists,
surfactants, indomethacin, bronchodilators, xanthines, cromolyn sodium, glucocorticoids,
thyroid hormones, and diuretics). The search in MEDLINE included the following MeSH
terms: bronchopulmonary dysplasia OR respiratory distress syndrome, newborn. We also
included chronic lung disease as a title and abstract search term. We included search terms
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for age: infant, newborn; and RCTs: randomized controlled trial. We performed an
additional search to identify independent early-phase studies by substituting the RCT
limitations for pilot studies: pilot projects. Finally, we reformatted and repeated our search
in EMBASE. The search was run on March 3, 2014.
Study selection
The search was conducted by a primary reviewer (KB). We included RCTs with BPD as a
primary or secondary outcome or a combined outcome of death or BPD. After title and
abstract screening followed by a full-text screening, we excluded publications that evaluated
modes of ventilation, routes of administration of the same drug (e.g., inhaled versus
systemic), cost effectiveness, or dosing strategy comparisons.
RCT characteristics
Our review focused on the following characteristics of RCTs:
Prior early-phase studies—By examining the references of each full-text RCT, we
determined whether a phase I and/or phase II study was performed prior to the RCT. A study
qualified as a phase I or phase II study if the tolerability and dosing of the drug was
evaluated (phase I) or if the intervention was tested for safety (phase II). Pharmacokinetic
(PK) studies for appropriate dosing were also included as early-phase trials. We similarly
included previous data referenced in the RCTs (not necessarily performed by the authors).
Definition of BPD—We classified definitions of BPD into 1 of 3 categories: oxygen
supplementation at 28 days, O2 at 36 weeks PMA, or the physiologic definition, described
as a room air challenge between 35 and 37 weeks PMA.11
In addition, we searched the Food and Drug Administration (FDA) website (www.fda.gov)
and other academic and professional websites (www.micromedexsolutions.com and
www.dailymed.org) to obtain labeling information and determine whether a drug was FDA-
approved for BPD prevention or treatment. We searched www.fda.gov to determine whether
the studies were performed under an Investigational New Drug (IND) application for BPD
prevention. Finally, we identified funding sources for each RCT as reported in the published
study.
We summarized the characteristics of the RCTs and categorized the information based on
the specific drug tested. Meta-analyses (e.g., Cochrane Collaboration) were analyzed to
categorize drugs into 2 groups: drugs that prevent BPD and drugs that do not prevent BPD.
If the meta-analysis found a statistically significant effect, then the drug was considered to
be favorable for preventing BPD. Conversely, if the meta-analysis did not find a statistically
significant effect, the drug was considered unfavorable. If there was no meta-analysis (e.g., a
single study was performed), we used the risk difference as reported by the authors to
determine favorability for the prevention of BPD.
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We identified 2026 publications for 21 drugs, including phase I and phase II studies, and
phase III RCTs. We excluded 565 duplicate studies identified by both searches in
MEDLINE and EMBASE leaving 1461 articles for review. After completing a title, abstract,
and full-text screening, we excluded 1364 publications that did not meet our inclusion
criteria. In addition, we separated 31 meta-analyses identified in the Cochrane
Collaboration. Our final review included 47 RCTs and 19 early-phase studies (Figure 1).
Early-phase data were referenced for 16 (76%) drugs (Table 1). A total of 11,953 infants
were enrolled in the 47 RCTs. Sample sizes ranged from 26–2712 infants. A combined
outcome of death or BPD was used as a primary end point in 29 (62%) RCTs. Fourteen
(30%) RCTs demonstrated a reduction in BPD as either a primary or secondary outcome.
Drugs that prevent BPD
We found 13 RCTs for 5 drugs (N enrolled=4,794) that demonstrated a reduction in BPD.
There was an FDA label for 3 of the 5 drugs (vitamin A, caffeine citrate, and
dexamethasone) for the neonatal population, although none for the prevention of BPD
(Table 1).
Vitamin A is FDA-labeled for use in prevention of vitamin A deficiency but is used off-label
for prevention of BPD. Two RCTs examined the use of vitamin A for BPD prevention in
856 infants.12,13 One trial found no difference between the incidence of BPD when infants
were treated with 2000 IU intramuscular vitamin A every other day for 2 weeks versus
placebo.12 The other trial found the relative risk (RR) of death or BPD—defined either as
oxygen requirement at 28 days or 36 weeks PMA—after treatment with 5000 IU
intramuscular vitamin A three times a week over four weeks was 0.89 (95% confidence
interval; 0.80–0.99)13; this study was preceded by a phase I dosing study.14 In a meta-
analysis, intramuscular vitamin A significantly reduced the incidence of BPD.15
Caffeine citrate is FDA-labeled for the treatment of apnea of prematurity for infants born
between 28 and 33 weeks gestational age. The Caffeine for Apnea of Prematurity (CAP)
trial examined 2006 infants treated with caffeine citrate for the primary composite outcome
of death, cerebral palsy, cognitive delay, deafness, or blindness at a corrected age of 18–21
months.16 A secondary analysis examined additional morbidities including BPD, necrotizing
enterocolitis, and retinopathy of prematurity. Infants treated with caffeine had lower risk of
BPD—defined as the need for oxygen at 36 weeks PMA—than infants in the placebo group
(RR=0.63 [0.52–0.73]).16 The investigators did not perform a pilot study prior to the RCT,
although they did reference prior data. However, none of the referenced data examined the
PK profile of caffeine in infants. A literature review in 2012 concluded that caffeine citrate
use in premature infants resulted in a significant reduction in BPD incidence with few side
effects.17
Dexamethasone is FDA-labeled for pediatric use in various conditions, including croup and
disorders of the endocrine system, but is not labeled for BPD prevention or treatment (Table
1).18 We identified 9 RCTs examining 1513 infants treated with dexamethasone with the
primary end point as BPD prevention,19–27 while an additional trial examined 188 infants
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and the incidence of chronic lung disease as a secondary end point28; 4 of the 10 trials used
a combined end point of BPD or death. Four studies demonstrated a decrease in BPD, but
only 1 used a combined outcome.20–23 One trial was preceded directly by a pilot study29;
however, this trial did not examine the PK or dosing profile of dexamethasone in premature
infants. BPD was defined as oxygen supplementation at 28 days in 6 trials and oxygen
supplementation at 36 weeks PMA in 4 trials; 2 trials used both the clinical and physiologic
definitions. Several Cochrane reviews examined different dosing regimens of corticosteroids
including early (<8 days), moderately early (7–14 days), and late (>7 days) administration of
the drug for the prevention or treatment of BPD. The consensus suggests that, although
administration of corticosteroids reduces BPD at 28 days and 36 weeks PMA, the benefit
does not outweigh the risk of adverse neurological outcomes in the long term.30–32 In 2010,
the American Academy of Pediatrics re-examined the evidence for use of postnatal
corticosteroids to prevent or treat BPD and concluded insufficient evidence to recommend
routine use but suggested the clinician should use his or her judgment for each individual
patient.33
We identified 2 drugs with single-center RCTs demonstrating a reduction in BPD. Inositol
was studied in 233 infants with a primary outcome of survival without BPD, defined as
respiratory distress at 28 days (clinical criteria for respiratory distress defined by presence of
tachypnea, dyspnea, supplemental O2 requirement, and hypercapnia)34 and 38 weeks PMA
or day of discharge; 71% of those given inositol survived without BPD compared with 55%
of those given placebo (p=0.005).35 Although inositol does not have an FDA indication for
BPD because of its classification as a naturally occurring substance, it is generally
recognized as safe. A recently published study also adds information regarding the
pharmacokinetics of inositol in preterm infants.36 A single trial of clarithromycin in 68
infants evaluated a primary outcome of eradication of Ureaplasma urealyticum and the
secondary outcome of incidence of BPD, defined as oxygen requirement at 36 weeks PMA
(2.9% incidence in those treated with clarithromycin vs. 36.4% in those not treated;
p<0.001).37 While clarithromycin does have FDA-labeled indications for a variety of
infectious diseases, it is not approved for use in infants <6 months of age. There are no
dosing data on clarithromycin for prevention of BPD. There were no meta-analyses for
inositol and clarithromycin, but based on single-center studies, inositol and clarithromycin
were classified as preventing BPD.
Drugs that do not reduce BPD
We found 32 RCTs for 16 drugs that did not reduce BPD. These studies enrolled 7159
infants and included surfactant, inhaled nitric oxide (iNO), selenium, hydrocortisone,
allopurinol, N-acetylcysteine, inhaled beclomethasone, azithromycin, estrogen and
progesterone, alpha-1-antitrypsin, inhaled salbutamol, superoxide dismutase, cromolyn
sodium, inhaled fluticasone, thyroxine, and zinc (Table 1). Four RCTs of surfactant reduced
the incidence of BPD.38–41 However, meta-analyses of surfactant have not consistently
supported a reduction in BPD for survivors.42–44 While 1 trial demonstrated reductions in
both the combined outcome of death or BPD (RR=0.73 [0.65–0.83]) and BPD alone
(RR=0.75 [0.61–0.92]),42 the other trial showed reductions in only the combined outcome
(RR=0.89 [0.82–0.97]).44 Although preliminary data were referenced in the surfactant trials,
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these were not PK, safety, or efficacy data consistent with early-phase trials. Two of 7 iNO
trials demonstrated a reduction in the incidence of BPD, but a meta-analysis did not show a
reduction.45
Seven (16%) RCTs were preceded by early-phase studies evaluating PK and/or safety and
efficacy: iNO,46 hydrocortisone,47 N-acetylcysteine,48 azithromycin,49–52 estrogen/
progesterone,53 inhaled salbutamol,54 and superoxide dismutase.55 Other therapeutics
(inhaled beclomethasone,56 cromolyn sodium,57 inhaled fluticasone,58 and zinc59)
referenced preliminary data in their studies, but the data were not PK or safety and efficacy
data.
BPD definition
Of the 47 RCTs in this review, 31 (66%) studies evaluated a combined outcome of death or
BPD, defined in 1 of 3 ways: oxygen supplementation at 28 days (n=14, 45%), oxygen
supplementation at 36 weeks PMA (n=22, 71%), or the physiologic definition (n=2, 6%).
Four (13%) trials used both oxygen supplementation at 28 days and oxygen supplementation
at 36 weeks PMA for evaluation of the primary outcome (Table 2). Only 2 trials54,60 used
the severity-based National Institute of Child Health and Human Development/National
Heart, Lung, and Blood Institute workshop definition, although these manuscripts were
published prior to the validation and publication of the workshop definition.61
Funding
We identified funding sources for 34 (72%) trials. Seven (15%) trials received funding from
the FDA and/or National Institutes of Health (NIH), including vitamin A, iNO,
hydrocortisone, inhaled beclomethasone, and thyroxine. Four trials on iNO were sponsored
by pharmaceutical companies, and 17 trials received international funding.
Discussion
Over the past 20 years, more than 20,000 infants have been enrolled in 47 RCTs and 19
early- phase trials examining the ability of 21 drugs to prevent BPD. Only 5 drugs from 13
trials reduced BPD. Of those, only vitamin A and dexamethasone have meta-analyses
demonstrating a reduction in the incidence of BPD.15,30–32 Caffeine, inositol, and
clarithromycin do not have meta-analyses due to a lack of multiple trials. Although the
majority of the RCTs referenced preliminary data, few had direct early-phase studies
evaluating the PK, dosing, safety, or preliminary efficacy of these drugs. In addition, the
definition of BPD varied between RCTs, resulting in inconsistent primary end points across
studies.
Two drugs, surfactant and iNO, were difficult to classify as favorable or unfavorable for the
prevention of BPD. While 4 (50%) of the surfactant trials had favorable results, the
Cochrane reviews of surfactant have not found a statistically significant difference between
treatment and placebo for BPD prevention. Surfactant offers great benefit to neonates for the
treatment of respiratory distress syndrome, but more trials examining the prevention of BPD
should be completed. The iNO trials also have a large amount of heterogeneity, and a
Cochrane review has not shown a statistically significant difference between treatment and
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placebo for BPD prevention. An ongoing phase II trial through the National Heart, Lung,
and Blood Institute is examining the effects of iNO on the primary outcome of incidence of
BPD or death (clinicaltrials.gov: NCT00955487). Additional trials on BPD prevention, such
as phase II, III, and IV trials for surfactant (clinicaltrials.gov: NCT01039285,
NCT00215540, NCT01022580) and phase II and III trials for iNO (clinicaltrials.gov:
NCT01503801, NCT00931632), may provide new evidence for these drugs to be classified
as favorable or unfavorable for BPD prevention.
Drug development is a lengthy and expensive process. Low study consent rates and lack of
consistent clinical end points make drug development in neonates particularly difficult. The
typical pathway for drug approval consists of approximately 10 steps that can take years to
decades to complete. After an IND application is filed and testing in human subjects is
underway, phase I studies in healthy volunteers for a dosing profile are conducted, and
phase II studies for efficacy in the population of interest occur before phase III trials
begin.62 Because the population in the neonatal intensive care unit is unhealthy, phase I
studies are often difficult to complete. Additional barriers to enrollment in neonates include
difficulty in obtaining parental consent, low prevalence of certain disease states, and the
inability to separate drug effects from natural disease progression in many neonates.
Despite the number of RCTs to prevent BPD, currently no drugs are FDA-labeled for the
prevention or treatment of BPD in the pediatric and neonatal population due to a lack of
favorable outcomes. The lack of labeled drugs may also be because the studies were not
completed under an IND, and the data were never submitted to the FDA for a label change.
In response to the 1994 Pediatric Labeling Rule, the Best Pharmaceuticals for Children Act
and Pediatric Research Equity Act were established in 2002 and 2003, respectively, to
increase drug studies for the pediatric population resulting in pediatric FDA labeling
changes. According to an Institute of Medicine statement regarding pediatric drug studies,
the therapeutic area that has the least number of drugs indicated for neonates is BPD,
emphasizing the need for more safety and efficacy studies.63 Efficacy data are often
extrapolated from adult studies, assuming the pathophysiology of the disease is similar in
the pediatric population and the evidence comes from an adequate number of adult studies.
However, the disease process is usually different in neonates, making extrapolation difficult
and often impossible. Therefore, the FDA recommends 2 adequate well-controlled trials,
including a PK study, followed by an appropriate safety and efficacy study.64–66
Despite the difficulties researchers face when studying drugs in neonates, it is necessary to
determine correct dosing in infants and children in a way similar to adult drug
development.67 Many of the trials in this review were phase III and not preceded by safety
and efficacy trials or adverse event analyses. Due to the barriers encountered when
attempting to enroll neonates in clinical trials, drug development is often compressed into 1
trial with safety, efficacy, dosing strategies, and adverse events analyzed simultaneously.
Our results support that this method has not been successful and exposes infants to therapies
that may not be safe or effective.
Successful drug development also relies on consistent definitions of the primary outcome.
The definition of BPD has changed from the original definition by Northway in 1967 to the
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current clinical5 and physiologic definitions,11 as well as the severity-based NIH workshop
definition.61 The physiologic definition provides an objective measure of oxygen
dependence by performing a room air challenge at 35–37 weeks PMA. When compared with
the clinical definition of BPD (oxygen supplementation at 36 weeks PMA), the physiologic
definition reduced overall rates of BPD, as well as the variability among centers.11 An NIH
panel further refined the definition of BPD with a severity-based definition dependent on the
amount of oxygen supplementation and respiratory support physiologically required at 36
weeks PMA. Importantly, the incidence of adverse pulmonary and neurodevelopmental
outcomes increased with worsening severity of BPD.61 Thus, the severity-based,
physiologic definition objectively defines infants with moderate or severe BPD as well as
identifies infants at increased risk for long-term impairment. Therefore, the severity-based,
physiologic definition of BPD should be consistently used when performing RCTs
evaluating a particular therapy or drug. We found the most common definition used was
merely oxygen supplementation at 36 weeks PMA. However, many of these trials did not
specify whether a physiological challenge was performed to confirm dependence on
supplemental oxygen. Additionally, only 2 trials explicitly used the severity-based definition
of BPD, although these trials were published prior to the NIH workshop definition. We
understand that some trials used a clinical definition before the physiologic definition was
validated in 2004, but 8 trials continued to use older clinical definitions (O2 at 28 days or 36
weeks PMA) after the NIH workshop and the physiologic definitions were published. The
use of the severity-based physiologic definition in RCTs can provide an objective
measurement of impaired lung function due to BPD and decrease measurement bias across
centers.11,61
Strengths of this review include the comprehensive nature of the search. There are currently
no other published reviews examining the wide range of drugs studied to treat or prevent
BPD. Study limitations include the focus on pharmaceutical therapy alone for prevention of
BPD. Due to the multifactorial etiology of BPD, there are many other therapies that
contribute to BPD and BPD prevention, including respiratory management (e.g., type of
ventilation, oxygen exposure) and nutritional strategies. Clinical practice has changed over
the last 20 years with new technologies such as high-flow nasal cannula, various nasal
cannula devices, and nasal intermittent positive pressure ventilation, which all may
contribute (or ameliorate ) BPD physiology. Future reviews should focus on trials aimed at
these alternate approaches. We also realize that we used the definitions of BPD as reported
in the literature, which likely are inadequate to describe what is happening physiologically.
Another limitation is the potential for publication bias. As indicated by 2 drugs with single-
center RCTs, small positive trials are often reported in the literature but often unreported
after expansion to a larger trial. This leads to difficulties with future drug development and
information dissemination. There is a need for publication of all trials, negative or positive,
supported by the pediatric community.68
Conclusion
The majority of RCTs of drugs for BPD prevention or treatment did not demonstrate
efficacy, and currently there are no drugs FDA-labeled for BPD prevention. Performing
early-phase studies (phase I and phase II) prior to phase III trials might provide important
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information that can be used to identify drugs and dosing strategies capable of preventing
BPD.
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Table 2
Definition of bronchopulmonary dysplasia by trial, N = 31 (66%)*
Outcome # RCTs
O2 at 28 days 14
O2 at 36 weeks PMA 22
Physiologic BPD 2
Severity-based 2
O2 at 28 days and 36 weeks PMA 4
*
Not all trials provided a definition; several trials had multiple definitions provided.
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